ANI Pharmaceuticals Reports Strong Q1, Raises 2026 Guidance, and Authorizes $100M Share Buyback
ANIP sits 56% above its 52-week low of $56.71.
Summary
ANI Pharmaceuticals announced robust first-quarter results, exceeding expectations, and raised its full-year 2026 financial guidance. The Board also authorized a significant $100 million share repurchase program.
Key Events · Earnings and Guidance · ANIP
-
Strong First Quarter 2026 Financial Results
The company reported net revenues of $237.5 million, a 20.5% increase year-over-year, and adjusted non-GAAP EBITDA of $63.0 million, up 24.1% year-over-year. Diluted GAAP income per share was $1.28, and adjusted non-GAAP diluted EPS was $2.05.
-
Raised Full-Year 2026 Financial Guidance
ANI Pharmaceuticals increased its 2026 total net revenue guidance to $1,080 million - $1,140 million, adjusted non-GAAP EBITDA to $285 million - $300 million, and adjusted non-GAAP diluted EPS to $9.19 - $9.69, reflecting strong performance and outlook.
-
Board Authorizes $100 Million Share Repurchase Program
The Board of Directors approved a new share repurchase program, allowing the company to buy back up to $100.0 million of common stock through May 2029, demonstrating confidence in the company's valuation and financial strength.
-
Key Product Performance Drives Growth
Cortrophin Gel net revenues increased 42.1% year-over-year to $75.1 million, and ILUVIEN net revenues rose 19.5% to $19.3 million, contributing significantly to the Rare Disease segment's 36.9% revenue growth.
Analysis · ANIP · Life Sciences
This 8-K filing details a highly positive quarter for ANI Pharmaceuticals, marked by strong revenue and EBITDA growth, particularly from its Rare Disease segment led by Cortrophin Gel. The company's decision to raise its full-year 2026 guidance for total net revenue, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS signals management's increased confidence in sustained performance. Furthermore, the authorization of a $100 million share repurchase program is a substantial commitment to returning value to shareholders and indicates a belief that the stock is undervalued. This combination of strong operational performance, optimistic outlook, and shareholder-friendly capital allocation is a significant positive for investors.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 41% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ANIP was trading at $88.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $56.71 to $99.50. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.